Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma—a highly aggressive and hard-to-treat form of skin cancer.

Adjuvant treatment with dabrafenib and trametinib may be more effective than observation or adjuvant treatment with a PD-1 inhibitor in patients with stage IIIA melanoma.

Overall, rates of new cancer diagnoses and cancer-related deaths have declined, according to the annual cancer statistics ...